{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:07:50Z","timestamp":1793423270881,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,12,5]]},"abstract":"\n Importance<\/jats:title>\n Epidemiological and genetic data have implicated lipoprotein(a) as a potentially modifiable risk factor for atherosclerotic disease and aortic stenosis, but there are no approved pharmacological treatments.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To assess the safety, tolerability, pharmacokinetics, and effects of lepodisiran on lipoprotein(a) concentrations after single doses of the drug; lepodisiran is a short interfering RNA directed at hepatic synthesis of apolipoprotein(a), an essential component necessary for assembly of lipoprotein(a) particles.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A single ascending-dose trial conducted at 5 clinical research sites in the US and Singapore that enrolled 48 adults without cardiovascular disease and with lipoprotein(a) serum concentrations of 75 nmol\/L or greater (or \u226530 mg\/dL) between November 18, 2020, and December 7, 2021; the last follow-up visit occurred on November 9, 2022.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized to receive placebo or a single dose of lepodisiran (4 mg, 12 mg, 32 mg, 96 mg, 304 mg, or 608 mg) administered subcutaneously.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the safety and tolerability of the single ascending doses of lepodisiran. The secondary outcomes included plasma levels of lepodisiran for 168 days after dose administration and changes in fasting lipoprotein(a) serum concentrations through a maximum follow-up of 336 days (48 weeks).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of the 48 participants enrolled (mean age, 46.8 [SD, 11.6] years; 35% were women), 1 serious adverse event occurred. The plasma concentrations of lepodisiran reached peak levels within 10.5 hours and were undetectable by 48 hours. The median baseline lipoprotein(a) concentration was 111 nmol\/L (IQR, 78 to 134 nmol\/L) in the placebo group, 78 nmol\/L (IQR, 50 to 152 nmol\/L) in the 4 mg of lepodisiran group, 97 nmol\/L (IQR, 86 to 107 nmol\/L) in the 12-mg dose group, 120 nmol\/L (IQR, 110 to 188 nmol\/L) in the 32-mg dose group, 167 nmol\/L (IQR, 124 to 189 nmol\/L) in the 96-mg dose group, 96 nmol\/L (IQR, 72 to 132 nmol\/L) in the 304-mg dose group, and 130 nmol\/L (IQR, 87 to 151 nmol\/L) in the 608-mg dose group. The maximal median change in lipoprotein(a) concentration was \u22125% (IQR, \u221216% to 11%) in the placebo group, \u221241% (IQR, \u221247% to \u221220%) in the 4 mg of lepodisiran group, \u221259% (IQR, \u221266% to \u221253%) in the 12-mg dose group, \u221276% (IQR, \u221276% to \u221275%) in the 32-mg dose group, \u221290% (IQR, \u221294% to \u221285%) in the 96-mg dose group, \u221296% (IQR, \u221298% to \u221295%) in the 304-mg dose group, and \u221297% (IQR, \u221298% to \u221296%) in the 608-mg dose group. At day 337, the median change in lipoprotein(a) concentration was \u221294% (IQR, \u221294% to \u221285%) in the 608 mg of lepodisiran group.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this phase 1 study of 48 participants with elevated lipoprotein(a) levels, lepodisiran was well tolerated and produced dose-dependent, long-duration reductions in serum lipoprotein(a) concentrations. The findings support further study of lepodisiran.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04914546<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.21835","type":"journal-article","created":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T16:30:32Z","timestamp":1699806632000},"page":"2075","source":"Crossref","is-referenced-by-count":235,"title":["Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)"],"prefix":"10.1001","volume":"330","author":[{"given":"Steven E.","family":"Nissen","sequence":"first","affiliation":[{"name":"Cleveland Clinic Center for Clinical Research, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Linnebjerg","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Shen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Center for Clinical Research, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosu","family":"Ma","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufen","family":"Lim","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura F.","family":"Michael","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Ruotolo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Gribble","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Center for Clinical Research, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Victorian Heart Institute, Monash University, Clayton, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"joi230131r1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies.","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"issue":"22","key":"joi230131r2","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"12","key":"joi230131r3","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"joi230131r4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"issue":"26","key":"joi230131r5","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease.","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"joi230131r6","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1038\/s41467-018-04668-w","article-title":"Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries.","volume":"9","author":"Zekavat","year":"2018","journal-title":"Nat Commun"},{"issue":"7","key":"joi230131r7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis.","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"joi230131r8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis.","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"11","key":"joi230131r9","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/jama.296.11.1363","article-title":"Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.","volume":"296","author":"Suk Danik","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"joi230131r10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"joi230131r11","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization.","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"joi230131r12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"issue":"3","key":"joi230131r13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease.","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"joi230131r14","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease.","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"joi230131r15","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels.","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"joi230131r16","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1161\/ATVBAHA.121.316290","article-title":"N-acetyl galactosamine targeting: paving the way for clinical application of nucleotide medicines in cardiovascular diseases.","volume":"41","author":"Biessen","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"joi230131r17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0304-3959(83)90088-X","article-title":"Assessment of chronic pain, I: aspects of the reliability and validity of the visual analogue scale.","volume":"16","author":"Carlsson","year":"1983","journal-title":"Pain"},{"key":"joi230131r19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/apm.1963.59.issue-3","article-title":"A new serum type system in man-the Lp system.","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"6","key":"joi230131r20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies.","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"joi230131r21","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial.","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"joi230131r22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study.","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"joi230131r23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a mendelian randomization analysis.","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"key":"joi230131r18","unstructured":"Brown? BD, Dudek? HT, Abrams? M, Han? W, Turanov? A. WO2022032288: compositions and methods for inhibiting LPA expression. October 2, 2022. Accessed October 18, 2023. https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2022032288&_cid=P22-LLKT14-93616-1"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2811935\/jama_nissen_2023_oi_230131_1701196141.26637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T11:31:42Z","timestamp":1701775902000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2811935"}},"subtitle":["A Randomized Dose-Ascending Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":23,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,12,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.21835","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,5]]}}}